Rohto’s Cirrhosis Cell Therapy Finds Japan Partner In Shionogi
In a sign of continued corporate interest in the regenerative and cell therapy area in Japan, Shionogi has acquired rights in this market to a novel cirrhosis treatment being developed by Rohto.
You may also be interested in...
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.